2-(5-methyl-1,3,4-oxadiazol-2-yl)benzoic acid | 898289-64-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(5-methyl-1,3,4-oxadiazol-2-yl)benzoic acid
• CAS: 898289-64-0
• 化学式: C₁₀H₈N₂O₃
• mdl: MFCD09880459
• 分子量: 204.185
• InChiKey: KBQBJFWYPQURSO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  76.2
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-(5-methyl-1,3,4-oxadiazol-2-yl)benzoic acid 、 (1S,2S)-1-methyl-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine 在 N-羟基-7-氮杂苯并三氮唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 二氯甲烷-D2 为溶剂， 反应 72.0h， 生成 2-(5-methyl-1,3,4-oxadiazol-2-yl)-N-[(1S,2S)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide
  参考文献：
  名称：

  NOVEL COMPOUNDS

  摘要：

  本发明提供了公式(I)的化合物及其药用盐，其中L、X、Ra、Rb、R1、R2和R3如规范中定义，以及其制备方法、含有它们的药物组合物以及它们在治疗中的用途。

  公开号：

  US20150232460A1
• 作为产物：
  描述：

  1-Acetyl-2-(o-carboxy-benzoyl)-hydrazin 在 四磷十氧化物 、 硫酸 作用下， 以82%的产率得到2-(5-methyl-1,3,4-oxadiazol-2-yl)benzoic acid
  参考文献：
  名称：

  1,3,4-Oxadiazoles for Crystal Engineering. Convenient Synthesis and Self-Assembly: Nonchiral Chains versus Chiral Helices

  摘要：

  A series of new 1,3,4-oxadiazoles containing carboxylic and halogen groups and a double bond have been synthesized in good yields and a multigram scale. This was achieved at room temperature from readily available 1,2-diacylhydrazines using a cheap condensation reagent (the solution of P2O5 in H2SO4). Single-crystal X-ray diffraction analysis has shown that all studied 1,3,4-oxadiazole-containing acids are self-assembled by intermolecular H-bonds into supramolecular zigzag chains or helices, depending on the tecton molecular structure and the type of H-bonding. Factors affecting helix formation have been found, and a Cambridge Structural Database (CSD) survey has been performed to support these findings. Moreover, it has been demonstrated that the tuning of the crystal structure leading to spontaneous symmetry breaking for supramolecular helices based on nonchiral molecules is possible even by as little change in molecular structure as a shift from an isopropyl substituent to a cyclopropyl. Subsequently, the studied 1,3,4-oxadiazole-containing acids and related compounds are found to be easily accessible building blocks for crystal engineering of new chiral materials with tunable supramolecular arrangement.

  DOI：

  10.1021/cg400649h

文献信息

• [EN] NOVEL N-[(PYRIMIDINYLOXY)PROPANYL]BENZAMIDES<br/>[FR] NOUVEAUX N-[(HÉTÉROARYLOXY)PROPANYL]HÉTÉROARYL CARBOXAMIDES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2017178338A1

  公开（公告）日：2017-10-19

  This invention relates to compounds of formula (I), a process for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions having an association with the orexin sub-type 1 receptor. Ar, R1, R2, R3, R4, R5 have meanings given in the description.

  这项发明涉及到式(I)的化合物，其制备方法，含有它们的药物组合物以及它们在治疗与促觉醒素亚型1受体相关的疾病中的应用。Ar，R1，R2，R3，R4，R5的含义如描述中所示。
• [EN] CYCLOPENTYLBENZAMIDE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF PSYCHOTIC AND COGNITIVE DISORDERS<br/>[FR] DÉRIVÉS DE CYCLOPENTYLBENZAMIDE ET LEUR UTILISATION POUR LE TRAITEMENT DE TROUBLES PSYCHOTIQUES OU COGNITIFS
  申请人：TAKEDA CAMBRIDGE LTD

  公开号：WO2015055994A1

  公开（公告）日：2015-04-23

  The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein n, L, X, Ra, Rb, R1, R2 and R3 their preparation, pharmaceutical compositions containing them and their use in therapy.

  本发明提供了式（I）的化合物及其药用盐，其中n，L，X，Ra，Rb，R1，R2和R3，它们的制备，含有它们的药物组合物以及它们在治疗中的用途。
• [EN] NOVEL N-[(PYRIDYLOXY)PROPANYL]BENZAMIDES<br/>[FR] NOUVEAUX N-[(PYRIDYLOXY)PROPANYL]BENZAMIDES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2017178340A1

  公开（公告）日：2017-10-19

  This invention relates to compounds of formula (I), a process for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions having an association with the orexin sub-type 1 receptor. Ar, R1, R2, R3, R4, R5, R6 and R7 have meanings given in the description.

  这项发明涉及式(I)的化合物，其制备方法，含有它们的药物组合物以及它们在治疗与促进素亚型1受体相关的疾病中的应用。Ar，R1，R2，R3，R4，R5，R6和R7的含义如描述中所示。
• Cyclopentylbenzamide Derivatives and their Use for the Treatment of Psychotic and Cognitive Disorders
  申请人：TAKEDA PHARMACEUTICAL COMPANY LIMITED

  公开号：US20160222030A1

  公开（公告）日：2016-08-04

  The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein n, L, X, R a , R b , R 1 , R 2 and R 3 their preparation, pharmaceutical compositions containing them and their use in therapy.

  本发明提供了式(I)的化合物及其药学上可接受的盐，其中n，L，X，Ra，Rb，R1，R2和R3，以及它们的制备方法、含有它们的药物组合物以及它们在治疗中的使用。
• Cycloalkyl and heterocycloalkyl compounds as orexin receptor antagonists
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US09156829B2

  公开（公告）日：2015-10-13

  The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein L, X, Ra, Rb, R1, R2 and R3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

  本发明提供了公式(I)的化合物及其药学上可接受的盐，其中L、X、Ra、Rb、R1、R2和R3如规范中所定义，以及其制备过程、含有它们的药物组合物和它们在治疗方面的用途。